Journal article
Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development
Y Hua, I Wang, B Liu, DJ Kelly, C Reid, D Liew, Y Zhou, BH Wang
Future Cardiology | FUTURE MEDICINE LTD | Published : 2017
Abstract
Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard therapies have been focused on blockade of renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and mineralocorticoid antagonists and the sympathetic nervous system with β-blockers. The natriuretic peptide system is a potential counter-regulatory system that promotes vasodilatation and natriuresis. Angiotensin receptor neprilysin inhibitors are a new class drug capable of blocking the renin-angiotensin-aldosterone system and enhancing the natriuretic peptide system to improve neurohormonal balance. The success..
View full abstractGrants
Funding Acknowledgements
BH Wang and his team at Centre of Cardiovascular Research and Education in Therapeutics received research support from Novartis to study LCZ696 in post-myocardial infarction and a mycoardial infarction plus subtotal nephrectomy in vivo studies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.